Home / Business and Economy / AstraZeneca Taps AI for Faster Clinical Trials
AstraZeneca Taps AI for Faster Clinical Trials
20 Oct
Summary
- AstraZeneca partners with Oracle to integrate AI.
- AI will identify patients and monitor safety signals.
- The collaboration aims to enhance clinical research efficiency.
AstraZeneca has announced a significant collaboration with Oracle, integrating advanced artificial intelligence and real-world data into its clinical research processes. This strategic move is designed to identify suitable patients for clinical trials with greater speed and accuracy.
The partnership will utilize AI to proactively monitor safety signals throughout the trial phases. This enhanced oversight aims to ensure patient well-being while also improving the overall efficiency and effectiveness of research.
By embracing these cutting-edge technologies, AstraZeneca seeks to revolutionize how clinical studies are conducted. The company anticipates a notable acceleration in bringing new treatments to patients through optimized research methodologies.
